Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Multiple Myeloma 60Lymphoma 56Leukemia, Myeloid, Acute 51Leukemia 50Lymphoma, Non-Hodgkin 48Precursor Cell Lymphoblastic Leukemia-Lymphoma 46Hodgkin Disease 36Myelodysplastic Syndromes 28Lymphoma, Large B-Cell, Diffuse 27Breast Neoplasms 24Lymphoma, Mantle-Cell 23Neuroblastoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Burkitt Lymphoma 17Lymphoma, Follicular 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Central Nervous System Neoplasms 13Lymphoma, Large-Cell, Immunoblastic 12Sarcoma 11Neoplasms, Plasma Cell 11Brain Neoplasms 11Recurrence 10Lymphoma, B-Cell, Marginal Zone 10Neoplasms 9Hematologic Neoplasms 9Congenital Abnormalities 9Myeloproliferative Disorders 8Leukemia, Myelomonocytic, Chronic 8Leukemia, Biphenotypic, Acute 8Graft vs Host Disease 8

Interventions

pegfilgrastim 5NPI 2358 3balugrastim 2Granulocyte Colony-Stimulating Factor 2Drug Therapy 2Doxorubicin 2Docetaxel 2Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Chemotherapy-induced Neutropenia × Granulocyte Colony-Stimulating Factor × Clear all
NCT03102606 2024-08-29

Protective-1

BeyondSpring Pharmaceuticals Inc.

Phase 3 Completed
105 enrolled 16 charts

Chemotherapy-induced Neutropenia

NCT04345900 2024-05-16

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

BeyondSpring Pharmaceuticals Inc.

Phase 2 Completed
55 enrolled 21 charts

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡